This research study is studying an investigational drug called EOC237 in Patients With Advanced Solid Tumor.
Eligibility
Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria:
* Advanced Solid Tumors for which standard curative or palliative measures do not exist or are no longer effective.
* Expected survival≥ 3 months.
* ECOG performance status 0-1.
* Good organ and marrow function.
Exclusion Criteria:
* Patients with a history of severe drug allergic reaction.
* Pregnant or lactating female subjects.
* Uncontrolled, significant intercurrent or recent illness.
* Corrected QT interval calculated by the Fridericia formula (QTcF) \> 480 ms per electrocardiogram (ECG)
* Concomitant use of certain medications
Primary outcome measure(s)
Proportion of subjects with dose-limiting toxicity (DLT) — Up to approximately 3 years Number of subjects who experienced DLT events during 28 days after first administration of EOC237, divided by the number of DLT evaluable Subjects
Determination of maximum tolerated dose (MTD) — Up to approximately 3 years
the recommended phase 2 dose (RP2D) — Up to approximately 3 years
Trial sites (1)
Facility
City
Region
Status
National Cancer Center/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.